세계의 지혈제 시장 : 유형별, 제형별, 용도별, 최종사용자별, 지역별 - 예측(-2030년)

The global hemostats market is projected to reach 4.0 billion in 2030 from USD 2.9 billion in 2025, at a CAGR of 6.4% during the forecast period."

The escalating demographic of the elderly is driving a significant uptick in the demand for surgical interventions, highlighting the pivotal role of hemostatic agents within modern healthcare. As individuals age, they become more susceptible to a range of chronic conditions necessitating surgical correction to restore or improve functional capacity. This includes procedures such as orthopedic joint replacements and more complex cardiovascular and gastrointestinal surgeries. Aging is associated with physiological changes, including diminished tissue resilience and an elevated propensity for hemorrhage. Consequently, the judicious application of hemostatic agents is critical for optimizing surgical outcomes in geriatric patients. With the global aging population on the rise, the demand for hemostatic products is projected to escalate correspondingly, underscoring their essential contribution to addressing the intricate surgical care requirements of older adults. Nonetheless, the prohibitive costs of advanced hemostatic technologies coupled with limited accessibility in resource-constrained environments may pose challenges to their broader implementation.

"Combination hemostats segment accounted for the highest growth rate in the hemostats market, by type, during the study period."

The hemostats market is bifurcated into oxidized regenerated cellulose-based hemostats, thrombin-based hemostats, combination hemostats, gelatin-based hemostats, collagen-based hemostats, and other hemostats on the basis of type. The market for hemostatic agents is experiencing rapid growth due to the superior efficacy of combination hemostats compared to monotherapy products. These advanced hemostatic agents operate through multiple mechanisms, which enhance their ability to control surgical hemorrhage effectively. Key benefits associated with these combination products include decreased intraoperative blood loss, expedited and reliable hemostasis, reduced convalescence times, and a lower frequency of transfusion requirements. Furthermore, the implementation of combination hemostats has been linked to improved patient outcomes, such as shortened hospital stays and faster recovery trajectories.

"Sponge hemostats segment accounted for the highest growth rate in the hemostats market, by formulation, during the forecast period."

The global hemostats market is bifurcated into matrix & gel hemostats, sheet & pad hemostats, sponge hemostats, and powder hemostats. The sponge hemostats segment is experiencing the most rapid growth due to an increasing reliance on sponge-based formulations among surgeons and healthcare professionals, attributed to several key advantages. These hemostatic sponges are highly absorbent, user-friendly, and conform well to irregular wound geometries, making them applicable to a wide range of surgical procedures. They facilitate prompt hemostasis, mitigate the risk of postoperative bleeding, and are frequently available in ready-to-use formats, eliminating the need for prior preparation. Furthermore, most sponge hemostats are bioresorbable, which removes the necessity for subsequent removal and minimizes potential complications. Recent advancements in material science have led to the development of sponge hemostats with enhanced biocompatibility and antimicrobial properties, further solidifying their clinical preference. These innovations not only improve the safety profile but also optimize their effectiveness in various surgical contexts.

"By application, the orthopedic surgery segment accounted for the largest share of the hemostats market in 2024."

The hemostats market has been segmented into orthopedic surgery, general surgery, neurological surgery, cardiovascular surgery, gynecological surgery, reconstructive surgery, and other surgical applications, based on application. In 2024, the orthopedic surgery segment dominated the hemostats market, a trend driven by a rising prevalence of lifestyle-related conditions such as arthritis, osteoporosis, and obesity, which often lead to musculoskeletal complications requiring surgical intervention. The demographic shift towards an aging population, which is more susceptible to degenerative bone and joint disorders, also significantly contributes to the increased demand for orthopedic surgical procedures. Moreover, the escalating incidence of sports-related injuries and traumatic fractures necessitates a more substantial number of surgical interventions where precise hemostatic control is crucial. The growing preference for minimally invasive orthopedic techniques, which prioritize effective hemostasis without compromising clinical outcomes, further fuels market demand. Additionally, improved healthcare accessibility in emerging markets, coupled with the availability of advanced hemostatic agents, is facilitating the broader adoption of these products in orthopedic surgical practices.

"By region, the Asia Pacific was the fastest-growing region in the hemostats market in 2024."

The global hemostats market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is poised for significant growth in the hemostats market over the forecast period, primarily driven by robust GDP growth and rising disposable incomes in emerging economies. These economic dynamics are facilitating increased healthcare expenditure among broader demographics. The demand for sophisticated surgical products, such as hemostats, is escalating due to a surge in surgical procedures, a higher prevalence of chronic diseases, and the ongoing modernization of healthcare infrastructures. Moreover, the market is propelled by the increasing integration of advanced medical technologies, extending even into rural areas. The rapid expansion of healthcare facilities, particularly hospitals and clinics in China and India, combined with government initiatives to enhance disease management awareness, are critical contributors to this growth. Additionally, the significant uptick in healthcare spending across numerous Asian nations has bolstered the purchasing power of healthcare providers, thereby expediting the adoption of innovative hemostatic agents within the region.

The break-up of the profile of primary participants in the hemostats market:

• By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
• By Designation: C-level - 27%, Director-level - 18%, and Others - 55%
• By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and Middle East & Africa- 4%

Prominent players in the hemostats market include Johnson & Johnson Services, Inc. (US), Baxter (US), Pfizer Inc. (US), B. Braun SE (Germany), BD (US), Teleflex Incorporated (US), Medtronic (Ireland), Hemostasis, LLC (US), Stryker ((US), Integra LifeSciences Corporation (US), Advanced Medical Solutions Group plc (UK), Samyang Corporation (South Korea), Marine Polymer Technologies, Inc. (US), GELITA MEDICAL (Germany), Dilon Technologies (US), Betatech Medical (Turkey), Meril Life Sciences Pvt. Ltd. (India), BioCer Development GmbH (Germany), Unilene (Peru), Katsan Medical Devices (Turkey), Tricol Biomedical (US), 3-D Matrix Medical Technology (Japan), Hemostat Medical GmbH (Germany), CELOX Medical Ltd. (UK), and Altaylar Medical (Turkey).

Research Coverage

The report analyzes the hemostats market, estimating the market size and potential for future growth across various segments, including end users, regions, applications, type, and formulation. Additionally, the report features a competitive analysis of the key players in the market, detailing their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report

The report provides valuable insights for market leaders and new entrants in the hemostats industry, offering approximate revenue figures for the overall market and its subsegments. It assists stakeholders in understanding the competitive landscape, enabling them to position their businesses better and develop effective go-to-market strategies. Additionally, the report highlights key market drivers, restraints, challenges, and opportunities, helping stakeholders gauge the current state of the market.

This report provides insights into the following pointers:

• Analysis of key drivers (growing volume of surgical procedures performed, rising focus on R&D, and increasing emphasis on effective blood loss management in patients during surgeries), restraints (side effects and allergic reactions associated with hemostats), opportunities (increasing growth opportunities in emerging economies), and challenges (stringent regulatory framework, dearth of skilled personnel for effective use of hemostats, and high cost of hemostats) influencing the growth of the hemostats market.
• Market Penetration: It provides detailed information on the product portfolios that major players in the global hemostats market offer. The report covers various segments: end user, region, application, type, and formulation.
• Product Enhancement/Innovation: Comprehensive details about new product launches and anticipated trends in the global hemostats market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the hemostats market across varied regions.
• Market Diversification: Comprehensive information about newly launched products and services, expanding markets, current advancements, and investments in the global hemostats market.
• Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings of products and services, and capacities of the major competitors in the global hemostats market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 MARKET SCOPE
  • 1.3.1 INCLUSIONS AND EXCLUSIONS
  • 1.3.2 MARKETS COVERED
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 UNIT CONSIDERED
• 1.6 STAKEHOLDERS
• 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key data from primary sources
    • 2.1.2.2 Key industry insights
• 2.2 MARKET SIZE ESTIMATION
• 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.4 MARKET SHARE ESTIMATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
  • 2.6.1 SCOPE-RELATED LIMITATIONS
  • 2.6.2 METHODOLOGY-RELATED LIMITATIONS
• 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN HEMOSTATS MARKET
• 4.2 ASIA PACIFIC HEMOSTATS MARKET, BY END USER AND COUNTRY
• 4.3 HEMOSTATS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.4 REGIONAL MIX: HEMOSTATS MARKET (2023-2030)
• 4.5 HEMOSTATS MARKET: DEVELOPED VS. DEVELOPING MARKETS, 2025 VS. 2030 (USD MILLION)

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Growing volume of surgical procedures performed
    • 5.2.1.2 Increasing focus on R&D
    • 5.2.1.3 Rising focus on effective blood loss management in patients during surgeries
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Side effects and allergic reactions associated with hemostats
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 High growth potential in emerging economies
    • 5.2.3.2 Growing number of hospitals
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Stringent regulatory requirements for hemostat products
    • 5.2.4.2 Lack of skilled personnel for effective use of hemostats
    • 5.2.4.3 High cost of hemostats
• 5.3 INDUSTRY TRENDS
  • 5.3.1 INCREASED POPULARITY OF COMBINATION HEMOSTATS
  • 5.3.2 CONSOLIDATION OF HOSPITALS
• 5.4 TECHNOLOGY ANALYSIS
  • 5.4.1 KEY TECHNOLOGIES
    • 5.4.1.1 Passive hemostats
    • 5.4.1.2 Chitosan-based hemostats
  • 5.4.2 COMPLEMENTARY TECHNOLOGIES
    • 5.4.2.1 Surgical adhesives
  • 5.4.3 ADJACENT TECHNOLOGIES
    • 5.4.3.1 Drug-eluting sutures for local therapeutic delivery
    • 5.4.3.2 Barbed sutures
• 5.5 PRICING ANALYSIS
  • 5.5.1 AVERAGE SELLING PRICE TREND, BY HEMOSTAT
  • 5.5.2 AVERAGE SELLING PRICE OF HEMOSTATS, BY REGION, 2022-2024 (USD)
• 5.6 ECOSYSTEM/MARKET MAP
• 5.7 REIMBURSEMENT SCENARIO
• 5.8 VALUE CHAIN ANALYSIS
• 5.9 PORTER'S FIVE FORCES ANALYSIS
  • 5.9.1 THREAT OF NEW ENTRANTS
  • 5.9.2 THREAT OF SUBSTITUTES
  • 5.9.3 BARGAINING POWER OF SUPPLIERS
  • 5.9.4 BARGAINING POWER OF BUYERS
  • 5.9.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.10 SUPPLY CHAIN ANALYSIS
• 5.11 TRADE ANALYSIS
  • 5.11.1 IMPORT DATA FOR HEMOSTATS (HS CODE: 300610), 2020-2024
  • 5.11.2 EXPORT DATA FOR HEMOSTATS (HS CODE: 300610), 2020-2024
• 5.12 REGULATORY LANDSCAPE
  • 5.12.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.12.2 REGULATORY FRAMEWORK
    • 5.12.2.1 North America
      • 5.12.2.1.1 US
      • 5.12.2.1.2 Canada
    • 5.12.2.2 Europe
    • 5.12.2.3 Asia Pacific
      • 5.12.2.3.1 Japan
      • 5.12.2.3.2 China
      • 5.12.2.3.3 India
• 5.13 PATENT ANALYSIS
  • 5.13.1 PATENT PUBLICATION TRENDS FOR HEMOSTATS MARKET
  • 5.13.2 JURISDICTION ANALYSIS: TOP APPLICANTS FOR PATENTS IN HEMOSTATS MARKET
• 5.14 KEY CONFERENCES & EVENTS
• 5.15 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.15.2 KEY BUYING CRITERIA
• 5.16 ADJACENT MARKET ANALYSIS
• 5.17 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.18 UNMET NEEDS/END-USER EXPECTATIONS
• 5.19 IMPACT OF ARTIFICIAL INTELLIGENCE (AI) ON HEMOSTATS MARKET
• 5.20 CASE STUDY ANALYSIS
  • 5.20.1 EGYPT'S INCURA LEVERAGES MACHINE LEARNING TO REINVENT TRAUMA HEMOSTASIS
  • 5.20.2 SOLE-SUPPLIER TRANSITION FOR HEMOSTATIC AGENTS AT OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER
• 5.21 INVESTMENT AND FUNDING SCENARIO
• 5.22 IMPACT OF US TARIFF - HEMOSTATS MARKET
  • 5.22.1 INTRODUCTION
  • 5.22.2 KEY TARIFF RATES
  • 5.22.3 PRICE IMPACT ANALYSIS
  • 5.22.4 IMPACT ON REGION
    • 5.22.4.1 US
    • 5.22.4.2 Europe
    • 5.22.4.3 Asia Pacific
  • 5.22.5 IMPACT ON END-USE INDUSTRIES

6 HEMOSTATS MARKET, BY TYPE

• 6.1 INTRODUCTION
• 6.2 OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS
  • 6.2.1 HIGH BIOCOMPATIBILITY TO DRIVE ITS ADOPTION
• 6.3 THROMBIN-BASED HEMOSTATS
  • 6.3.1 DEVELOPMENTS IN RECOMBINANT THROMBIN PRODUCTS TO SUPPORT GROWTH
• 6.4 COMBINATION HEMOSTATS
  • 6.4.1 ADVANCEMENTS IN COMBINATION MATERIALS TO DRIVE MARKET
• 6.5 GELATIN-BASED HEMOSTATS
  • 6.5.1 HIGH ELASTICITY OFFERED BY GELATIN-BASED HEMOSTATS TO BOOST DEMAND
• 6.6 COLLAGEN-BASED HEMOSTATS
  • 6.6.1 LOW COST AND REDUCED RISK OF DISEASE TRANSMISSION TO PROMOTE ADOPTION OF COLLAGEN-BASED HEMOSTATS
• 6.7 OTHER HEMOSTATS

7 HEMOSTATS MARKET, BY FORMULATION

• 7.1 INTRODUCTION
• 7.2 MATRIX & GEL HEMOSTATS
  • 7.2.1 ABILITY OF MATRIX & GEL HEMOSTATS TO ENHANCE PLATELET AGGREGATION TO BOOST MARKET
• 7.3 SHEET & PAD HEMOSTATS
  • 7.3.1 ABILITY TO CUT SHEET & PAD HEMOSTATS INTO ANY SHAPE OR SIZE TO FUEL ADOPTION
• 7.4 SPONGE HEMOSTATS
  • 7.4.1 GROWING ACCEPTANCE OF SPONGE HEMOSTATS TO DRIVE DEMAND
• 7.5 POWDER HEMOSTATS
  • 7.5.1 ABILITY TO SPRAY POWDER FORMULATIONS DIRECTLY ON WOUNDS TO DRIVE DEMAND

8 HEMOSTATS MARKET, BY APPLICATION

• 8.1 INTRODUCTION
• 8.2 ORTHOPEDIC SURGERY
  • 8.2.1 INCREASING INCIDENCE OF SPORTS INJURIES TO SUPPORT MARKET GROWTH
• 8.3 GENERAL SURGERY
  • 8.3.1 INCREASING NUMBER OF HERNIA REPAIR PROCEDURES TO DRIVE GROWTH
• 8.4 NEUROLOGICAL SURGERY
  • 8.4.1 GROWING PREVALENCE OF NEUROLOGICAL DISORDERS TO DRIVE MARKET
• 8.5 CARDIOVASCULAR SURGERY
  • 8.5.1 RISING PREVALENCE OF CVD TO DRIVE ADOPTION OF HEMOSTATS
• 8.6 RECONSTRUCTIVE SURGERY
  • 8.6.1 GROWING NUMBER OF COSMETIC SURGERIES TO SUPPORT MARKET GROWTH
• 8.7 GYNECOLOGICAL SURGERY
  • 8.7.1 GROWING USE OF HEMOSTATS IN C-SECTION PROCEDURES TO CONTROL SURGICAL BLEEDING TO SUPPORT GROWTH
• 8.8 OTHER SURGICAL APPLICATIONS

9 HEMOSTATS MARKET, BY END USER

• 9.1 INTRODUCTION
• 9.2 HOSPITALS
  • 9.2.1 GROWING ADOPTION OF MINIMALLY INVASIVE SURGERIES TO BOOST ADOPTION OF HEMOSTATS
• 9.3 SPECIALTY CLINICS
  • 9.3.1 EXPANDING SPECIALTY CLINICS TO PROMOTE MARKET GROWTH
• 9.4 OTHERS

10 HEMOSTATS MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 10.2.2 US
    • 10.2.2.1 Strong healthcare infrastructure to support uptake of hemostats
  • 10.2.3 CANADA
    • 10.2.3.1 Growing geriatric population and increasing volume of surgeries to drive demand
• 10.3 EUROPE
  • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 10.3.2 GERMANY
    • 10.3.2.1 High healthcare expenditure in Germany to drive market
  • 10.3.3 UK
    • 10.3.3.1 Growing volume of hernia repair and cardiovascular surgeries to drive market
  • 10.3.4 FRANCE
    • 10.3.4.1 Presence of well-established healthcare system to drive market growth
  • 10.3.5 ITALY
    • 10.3.5.1 Increasing volume of surgeries to drive demand for hemostats
  • 10.3.6 SPAIN
    • 10.3.6.1 Growing healthcare budget and rising efforts to boost local manufacturing of medical products to drive market
  • 10.3.7 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 10.4.2 CHINA
    • 10.4.2.1 Growing number of hospitals and healthcare policy reforms to drive growth
  • 10.4.3 JAPAN
    • 10.4.3.1 Strong healthcare system and rising geriatric population to support market growth
  • 10.4.4 INDIA
    • 10.4.4.1 Rising healthcare awareness and favorable government support to drive market
  • 10.4.5 AUSTRALIA
    • 10.4.5.1 Well-established healthcare infrastructure to drive adoption of hemostats
  • 10.4.6 SOUTH KOREA
    • 10.4.6.1 Growing number of cosmetic surgeries to drive demand for hemostats
  • 10.4.7 REST OF ASIA PACIFIC
• 10.5 LATIN AMERICA
  • 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 10.5.2 BRAZIL
    • 10.5.2.1 Brazil to dominate Latin American market for hemostats
  • 10.5.3 MEXICO
    • 10.5.3.1 Low-cost surgeries to drive medical tourism in Mexico
  • 10.5.4 REST OF LATIN AMERICA
• 10.6 MIDDLE EAST & AFRICA
  • 10.6.1 STRENGTHENING OF HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
  • 10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 10.6.3 GCC COUNTRIES
  • 10.6.4 REST OF MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE

• 11.1 INTRODUCTION
• 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN HEMOSTATS MARKET
• 11.3 REVENUE SHARE ANALYSIS
• 11.4 MARKET SHARE ANALYSIS
• 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 11.5.1 STARS
  • 11.5.2 EMERGING LEADERS
  • 11.5.3 PERVASIVE PLAYERS
  • 11.5.4 PARTICIPANTS
  • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 11.5.5.1 Company footprint
    • 11.5.5.2 Region footprint
    • 11.5.5.3 Type footprint
    • 11.5.5.4 Formulation footprint
• 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 11.6.1 PROGRESSIVE COMPANIES
  • 11.6.2 RESPONSIVE COMPANIES
  • 11.6.3 DYNAMIC COMPANIES
  • 11.6.4 STARTING BLOCKS
  • 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 11.6.5.1 Detailed list of key startups/SMEs
    • 11.6.5.2 Competitive benchmarking of key startups/SMEs
• 11.7 VALUATION & FINANCIAL METRICS
  • 11.7.1 FINANCIAL METRICS
  • 11.7.2 COMPANY VALUATION
• 11.8 BRAND/PRODUCT COMPARISON
• 11.9 R&D EXPENDITURE OF KEY PLAYERS
• 11.10 COMPETITIVE SCENARIO
  • 11.10.1 PRODUCT LAUNCHES AND APPROVALS
  • 11.10.2 DEALS
  • 11.10.3 EXPANSIONS
  • 11.10.4 OTHER DEVELOPMENTS

12 COMPANY PROFILES

• 12.1 KEY PLAYERS
  • 12.1.1 JOHNSON & JOHNSON SERVICES, INC.
    • 12.1.1.1 Business overview
    • 12.1.1.2 Products offered
    • 12.1.1.3 Recent developments
      • 12.1.1.3.1 Product approvals & launches
      • 12.1.1.3.2 Deals
      • 12.1.1.3.3 Other developments
    • 12.1.1.4 MnM view
      • 12.1.1.4.1 Right to win
      • 12.1.1.4.2 Strategic choices
      • 12.1.1.4.3 Weaknesses and competitive threats
  • 12.1.2 BAXTER
    • 12.1.2.1 Business overview
    • 12.1.2.2 Products offered
    • 12.1.2.3 Recent developments
      • 12.1.2.3.1 Product approvals & launches
      • 12.1.2.3.2 Other developments
    • 12.1.2.4 MnM view
      • 12.1.2.4.1 Right to win
      • 12.1.2.4.2 Strategic choices
      • 12.1.2.4.3 Weaknesses and competitive threats
  • 12.1.3 PFIZER INC.
    • 12.1.3.1 Business overview
    • 12.1.3.2 Products offered
    • 12.1.3.3 Recent developments
    • 12.1.3.4 MnM view
      • 12.1.3.4.1 Right to win
      • 12.1.3.4.2 Strategic choices
      • 12.1.3.4.3 Weaknesses and competitive threats
  • 12.1.4 B. BRAUN SE
    • 12.1.4.1 Business overview
    • 12.1.4.2 Products offered
    • 12.1.4.3 Recent developments
    • 12.1.4.4 MnM view
      • 12.1.4.4.1 Right to win
      • 12.1.4.4.2 Strategic choices
      • 12.1.4.4.3 Weaknesses and competitive threats
  • 12.1.5 BECTON, DICKINSON AND COMPANY (BD)
    • 12.1.5.1 Business overview
    • 12.1.5.2 Products offered
    • 12.1.5.3 Recent developments
      • 12.1.5.3.1 Other developments
    • 12.1.5.4 MnM view
      • 12.1.5.4.1 Right to win
      • 12.1.5.4.2 Strategic choices
      • 12.1.5.4.3 Weaknesses and competitive threats
  • 12.1.6 TELEFLEX INCORPORATED
    • 12.1.6.1 Business overview
    • 12.1.6.2 Products offered
    • 12.1.6.3 Recent developments
      • 12.1.6.3.1 Product approvals & launches
      • 12.1.6.3.2 Deals
      • 12.1.6.3.3 Other developments
  • 12.1.7 MEDTRONIC PLC
    • 12.1.7.1 Business overview
    • 12.1.7.2 Products offered
    • 12.1.7.3 Recent developments
      • 12.1.7.3.1 Product approvals & launches
      • 12.1.7.3.2 Expansions
  • 12.1.8 HEMOSTASIS, LLC
    • 12.1.8.1 Business overview
    • 12.1.8.2 Products offered
    • 12.1.8.3 Recent developments
      • 12.1.8.3.1 Deals
  • 12.1.9 STRYKER
    • 12.1.9.1 Business overview
    • 12.1.9.2 Products offered
    • 12.1.9.3 Recent developments
      • 12.1.9.3.1 Expansions
  • 12.1.10 INTEGRA LIFESCIENCES
    • 12.1.10.1 Business overview
    • 12.1.10.2 Products offered
  • 12.1.11 ADVANCED MEDICAL SOLUTIONS GROUP PLC
    • 12.1.11.1 Business overview
    • 12.1.11.2 Products offered
    • 12.1.11.3 Recent developments
      • 12.1.11.3.1 Deals
  • 12.1.12 SAMYANG CORPORATION
    • 12.1.12.1 Business overview
    • 12.1.12.2 Products offered
• 12.2 OTHER PLAYERS
  • 12.2.1 MARINE POLYMER TECHNOLOGIES, INC.
  • 12.2.2 GELITA MEDICAL
  • 12.2.3 DILON TECHNOLOGIES
  • 12.2.4 BETATECH MEDICAL
  • 12.2.5 MERIL LIFE SCIENCES PVT. LTD.
  • 12.2.6 BIOCER DEVELOPMENT GMBH
  • 12.2.7 UNILENE
  • 12.2.8 KATSAN MEDICAL DEVICES
  • 12.2.9 TRICOL BIOMEDICAL
  • 12.2.10 3-D MATRIX MEDICAL TECHNOLOGY
  • 12.2.11 HEMOSTAT MEDICAL GMBH
  • 12.2.12 CELOX MEDICAL LTD.
  • 12.2.13 ALTAYLAR MEDICAL

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 CUSTOMIZATION OPTIONS
• 13.4 RELATED REPORT
• 13.5 AUTHOR DETAILS